Agarwal K, Yousaf N, Morganstein D. Glucocorticoid use and complications following immune checkpoint inhibitor use in melanoma. Clin Med (Lond). 2020 Mar;20(2):163–8. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7081795/
Billmeier U, Dieterich W, Neurath MF, Atreya R. Molecular mechanism of action of anti-tumor necrosis factor antibodies in inflammatory bowel diseases. World Journal of Gastroenterology. 2016 Nov 14;22(42):9300–13. https://www.wjgnet.com/1007-9327/full/v22/i42/9300.htm
Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM, et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. JCO. 2018 Jun 10;36(17):1714–68.
https://ascopubs.org/doi/10.1200/JCO.2017.77.6385
Chaar M, Kamta J, Ait-Oudhia S. Mechanisms, monitoring, and management of tyrosine kinase inhibitors-associated cardiovascular toxicities [Internet]. OncoTargets and Therapy. 2018 [cited 2021 Apr 25]. Available from: https://www.dovepress.com/mechanisms-monitoring-and-management-of-tyrosine-kinase-inhibitors-ass-peer-reviewed-fulltext-article-OTT
Chhabra N, Kennedy J. A Review of Cancer Immunotherapy Toxicity: Immune Checkpoint Inhibitors. J Med Toxicol [Internet]. 2021 Apr 7 [cited 2021 Apr 25]; https://doi.org/10.1007/s13181-021-00833-8
Crisci S, Di Francia R, Mele S, Vitale P, Ronga G, De Filippi R, et al. Overview of Targeted Drugs for Mature B-Cell Non-hodgkin Lymphomas. Frontiers in Oncology [Internet]. 2019 [cited 2022 May 13];9. Available from: https://www.frontiersin.org/article/10.3389/fonc.2019.00443
Das S, Ariizumi K, Cruz PD. T-CELL INHIBITORS: A BENCH-TO-BEDSIDE REVIEW. Dermatitis. 2012 Sep;23(5):195–202. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3485635/
Dumoulin DW, Visser S, Cornelissen R, van Gelder T, Vansteenkiste J, von der Thusen J, et al. Renal Toxicity From Pemetrexed and Pembrolizumab in the Era of Combination Therapy in Patients With Metastatic Nonsquamous Cell NSCLC. Journal of Thoracic Oncology. 2020 Sep 1;15(9):1472–83. https://www.sciencedirect.com/science/article/pii/S1556086420303361
Elias AW, Kasi PM, Stauffer JA, Thiel DD, Colibaseanu DT, Mody K, et al. The Feasibility and Safety of Surgery in Patients Receiving Immune Checkpoint Inhibitors: A Retrospective Study. Front Oncol [Internet]. 2017 Jun 12 [cited 2021 Apr 28];7. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5466999/
Fragulidis G, Pantiora E, Michalaki V, Kontis E, Primetis E, Vezakis A, et al. Immune-related intestinal pseudo-obstruction associated with nivolumab treatment in a lung cancer patient. J Oncol Pharm Pract. 2019 Mar;25(2):487–91.
Gutierrez C, McEvoy C, Munshi L, Stephens RS, Detsky ME, Nates JL, et al. Critical Care Management of Toxicities Associated With Targeted Agents and Immunotherapies for Cancer: Critical Care Medicine. 2020 Jan;48(1):10–21. http://journals.lww.com/00003246-202001000-00003
Helmink BA, Roland CL, Kiernan CM, Wargo JA. Toxicity of Immune Checkpoint Inhibitors: Considerations for the Surgeon. Ann Surg Oncol. 2020 May 1;27(5):1533–45. https://doi.org/10.1245/s10434-019-08183-0
Ibrahimi S, Machiorlatti M, Vesely SK, Malla M, Modhia F, Jones SA, et al. Incidence of Vascular Thromboembolic Events in Patients Receiving Immunotherapy: A Single Institution Experience. Blood. 2017 Dec 7;130(Supplement 1):4864–4864. https://doi.org/10.1182/blood.V130.Suppl_1.4864.4864
Joseph A, Simonaggio A, Stoclin A, Vieillard-Baron A, Geri G, Oudard S, et al. Immune-related adverse events: a retrospective look into the future of oncology in the intensive care unit. Annals of Intensive Care. 2020 Oct 16;10(1):143. https://doi.org/10.1186/s13613-020-00761-w
Kounis NG. Coronary Hypersensitivity Disorder: The Kounis Syndrome. Clinical Therapeutics. 2013 May 1;35(5):563–71. https://www.clinicaltherapeutics.com/article/S0149-2918(13)00078-7/abstract
Lemiale V, Meert A-P, Vincent F, Darmon M, Bauer PR, Van de Louw A, et al. Severe toxicity from checkpoint protein inhibitors: What intensive care physicians need to know? Ann Intensive Care. 2019 Feb 1;9(1):25. https://doi.org/10.1186/s13613-019-0487-x
Lewis AL, Chaft J, Girotra M, Fischer GW. Immune checkpoint inhibitors: a narrative review of considerations for the anaesthesiologist. British Journal of Anaesthesia. 2020 Mar 1;124(3):251–60. https://www.bjanaesthesia.org.uk/article/S0007-0912(19)30972-9/abstract
Liu MM, Reidy AB, Saatee S, Collard CD. Perioperative Steroid Management: Approaches Based on Current Evidence. Anesthesiology. 2017 Jul 1;127(1):166–72. https://doi.org/10.1097/ALN.0000000000001659
Longoria TC, Tewari KS. Evaluation of the pharmacokinetics and metabolism of pembrolizumab in the treatment of melanoma. Expert Opin Drug Metab Toxicol. 2016 Oct;12(10):1247–53. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5613934/
Martins F, Sofiya L, Sykiotis GP, Lamine F, Maillard M, Fraga M, et al. Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nature Reviews Clinical Oncology. 2019 Sep;16(9):563–80. https://www.nature.com/articles/s41571-019-0218-0
Mays AC, Yarlagadda B, Achim V, Jackson R, Pipkorn P, Huang AT, et al. Examining the relationship of immunotherapy and wound complications following flap reconstruction in patients with head and neck cancer. Head & Neck. 2021;43(5):1509–20. https://onlinelibrary.wiley.com/doi/abs/10.1002/hed.26601
Puzanov I, Diab A, Abdallah K, Bingham CO, on behalf of the Society for Immunotherapy of Cancer Toxicity Management Working Group, Brogdon C, et al. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. j immunotherapy cancer. 2017 Dec;5(1):95. https://jitc.bmj.com/lookup/doi/10.1186/s40425-017-0300-z
Rezaieyazdi Z, Sahebari M, Khodashahi M. Preoperative Evaluation and Management of Patients Receiving Biologic Therapies. Arch Bone Jt Surg. 2019 May;7(3):220–8. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6578481/
Salinas C, Renner A, Rojas C, Samtani S, Burotto M. Primary Adrenal Insufficiency during Immune Checkpoint Inhibitor Treatment: Case Reports and Review of the Literature. CRO. 2020;13(2):621–6. https://www.karger.com/Article/FullText/507652
Simoneaux R, Shafer SL. Immune Checkpoint Inhibitor Therapies in Cancer Treatment. ASA Monitor. 2022 Sep;86(9):1-13.
https://doi.org/10.1097/01.ASM.0000874188.34355.5e
Spiers L, Coupe N, Payne M. Toxicities associated with checkpoint inhibitors—an overview. Rheumatology. 2019 Dec 1;58(Supplement_7):vii7–16. https://doi.org/10.1093/rheumatology/kez418
Wang DY, Salem J-E, Cohen JV, Chandra S, Menzer C, Ye F, et al. Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis. JAMA Oncol. 2018 Dec 1;4(12):1721. http://oncology.jamanetwork.com/article.aspx?doi=10.1001/jamaoncol.2018.3923
Supportive Care and Treatment Related Issues [Internet]. ASCO. [cited 2021 Apr 28]. Available from: https://www.asco.org/research-guidelines/quality-guidelines/guidelines/supportive-care-and-treatment-related-issues
]]>If you attended the ASA Virtual Meeting presentation on October 3rd, or are watching the recording, here are the recommended readings about Sponsorship, with links to the articles. Each will open in a new window.
Of note, the most useful references on this topic, as well as the others in our SnapTalk presentations, do not come from typical medical references, but from the various business and tech sites that talk about professional development.
I may have periodic updates, but will note which items are new.
]]>